NASDAQ · LLY
Healthcare · Drug Manufacturers - General
$1,160.08
Up+$0.06 (+0.01%)
Updated Sep 3, 2026, 6:08 AM
SID Score
6.3/10
Composite research score
Smart Money
45/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
LLY closed at $1,160.08 after 21 trading sessions, down 0.84% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 2, 2026 | $1,164.15 | $1,187.83 | $1,158.00 | $1,160.08 | 2.45M |
| Sep 1, 2026 | $1,188.00 | $1,188.325 | $1,156.8501 | $1,160.00 | 2.52M |
| Aug 31, 2026 | $1,168.47 | $1,171.4479 | $1,147.00 | $1,156.73 | 3.06M |
| Aug 28, 2026 | $1,172.66 | $1,180.00 | $1,162.93 | $1,174.61 | 2.45M |
| Aug 27, 2026 | $1,182.25 | $1,190.11 | $1,171.71 | $1,176.10 | 2.74M |
| Aug 26, 2026 | $1,234.00 | $1,235.775 | $1,180.01 | $1,189.41 | 3.01M |
| Aug 25, 2026 | $1,249.00 | $1,264.73 | $1,229.79 | $1,233.66 | 2.14M |
| Aug 24, 2026 | $1,262.14 | $1,262.14 | $1,230.95 | $1,246.93 | 1.67M |
| Aug 21, 2026 | $1,232.00 | $1,271.22 | $1,230.00 | $1,255.40 | 2.5M |
| Aug 20, 2026 | $1,274.13 | $1,280.28 | $1,243.2301 | $1,244.40 | 2.62M |
| Aug 19, 2026 | $1,245.81 | $1,292.65 | $1,240.54 | $1,280.34 | 4.54M |
| Aug 18, 2026 | $1,200.00 | $1,228.47 | $1,194.01 | $1,225.73 | 2.51M |
| Aug 17, 2026 | $1,175.20 | $1,198.52 | $1,163.50 | $1,183.16 | 1.81M |
| Aug 14, 2026 | $1,194.01 | $1,199.00 | $1,171.1956 | $1,180.16 | 2.27M |
| Aug 13, 2026 | $1,238.30 | $1,240.10 | $1,206.00 | $1,209.00 | 1.93M |
| Aug 12, 2026 | $1,201.73 | $1,226.50 | $1,191.08 | $1,220.28 | 1.94M |
| Aug 11, 2026 | $1,230.65 | $1,237.9999 | $1,209.53 | $1,215.02 | 2.11M |
| Aug 10, 2026 | $1,185.01 | $1,231.94 | $1,184.405 | $1,231.94 | 3.01M |
| Aug 7, 2026 | $1,188.00 | $1,196.80 | $1,161.2001 | $1,185.71 | 2.9M |
| Aug 6, 2026 | $1,196.55 | $1,230.88 | $1,173.50 | $1,191.94 | 3.42M |
| Aug 5, 2026 | $1,174.00 | $1,216.94 | $1,138.4301 | $1,169.86 | 6.45M |
The latest Smart Investors Daily articles mentioning LLY.
LLY research
Company profile and research snapshot.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Truist Securities | Buy | — |
| Aug 6, 2026 | Wells Fargo | Overweight | — |
| Aug 6, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 15, 2026 | Citigroup | Buy | — |
| Jul 14, 2026 | Bernstein | Outperform | — |
Generated Sep 2, 2026, 9:19 PM
Eli Lilly's stock is essentially flat today despite a flurry of positive developments, suggesting the market has already priced in much of the good news. The company is navigating a complex landscape where its GLP-1 dominance faces new competitive and regulatory pressures, even as strategic moves like the Merida Biosciences acquisition signal confidence in diversification.
Bottom line: Eli Lilly remains well-positioned as the GLP-1 market leader with diversification efforts underway, but today's flat price action reflects an already-optimistic market view with significant expectations built in. Investors should monitor insurance coverage trends, competitive clinical data, and the success of the Merida acquisition as key catalysts, while remaining cautious about valuation risk given the stock's strong recent run.
Yahoo · Sep 2, 2026
President Donald Trump has secured new drug pricing agreements with nine pharmaceutical companies, with an aim to align the prices of drugs in the U.S. with international prices. The companies include Alcon Inc., Astellas Pharma, BeOne Medicines Ltd., BridgeBio, CSL,...
Yahoo · Sep 2, 2026
The drug giant added to its immunotherapy portfolio.
Yahoo · Sep 2, 2026
HIMS raised its 2026 revenue outlook after Q2 sales jumped 38.2%, but margin contraction and an $86.3 million net loss highlighted growth costs.
Yahoo · Sep 2, 2026
Before the eighty-five percent surge, the company's pipeline story was getting louder just as its revenue trajectory was getting quieter.
Interpretive context generated from the platform’s current data sources.
Eli Lilly and Company shares closed at $1,159.93, reflecting a single-session decline of 1.66%, per SID market data. Despite this near-term pullback, LLY has demonstrated resilience across longer timeframes, posting a 0.69% gain over the trailing one-month period, a 6.89% advance over three months, and a 14.02% return over the past twelve months. The stock currently trades below its 50-day moving average of $1,188.00 but remains well above its 200-day moving average of $1,056.21, indicating that the broader uptrend remains intact despite recent softness. The 14-day relative strength index registers at 40.0, suggesting the stock is approaching oversold territory without yet reaching that threshold. LLY carries a beta of 0.369, according to Massive/Polygon data, reflecting significantly lower volatility than the broader market. Average daily trading volume stands at approximately 3.80 million shares, supporting a market capitalization of roughly $906.5 billion.
Eli Lilly trades at a price-to-earnings ratio of 49.16, a significant premium relative to the broader Healthcare sector, according to SID market data. This elevated multiple reflects the market's pricing of substantial future growth, particularly tied to the company's GLP-1 receptor agonist portfolio. The PEG ratio stands at 1.47, suggesting the valuation is moderately above a growth-adjusted fair value benchmark of 1.0 but remains within a range historically tolerated for high-growth pharmaceutical names. The price-to-book ratio registers at 38.04, per SEC filings, underscoring the degree to which intangible assets, including intellectual property and pipeline value, dominate the company's market valuation. Eli Lilly offers a modest dividend yield of approximately 0.59%, positioning it as a growth-oriented rather than income-oriented holding within the healthcare landscape. The company's near-$907 billion market capitalization ranks it among the most valuable pharmaceutical companies globally.
Eli Lilly's composite smart money score stands at 45 out of 100, registering a neutral signal, per SID market data. The institutional component scores a perfect 25 out of 25, reflecting overwhelming conviction among large asset managers and fund complexes, which represents the strongest possible reading in this category. Conversely, the insider activity component scores just 4.1 out of 25, despite 14 insider transactions recorded over the past 90 days according to SEC Form 4 filings. Of those transactions, 9 were purchases and 5 were sales, indicating a modest net buying bias among corporate officers and directors. The dark pool activity score registers at 9.2 out of 25, suggesting moderate but not outsized block trading interest from institutional desks. Congressional trading activity scores 6.4 out of 25, per 13F institutional filings and congressional disclosure records, indicating limited but present legislative member activity in the stock. The divergence between institutional strength and other components produces the overall neutral composite reading.
Eli Lilly has delivered a consistent pattern of earnings beats across its three most recent reporting periods, according to company earnings reports. In the February 2026 quarter, the company posted earnings per share of $7.54 against an analyst consensus estimate of $6.96, representing a $0.58 positive surprise. Performance accelerated in the April 2026 quarter, with actual EPS of $8.55 exceeding the $6.85 estimate by $1.70. The August 2026 quarter continued the trend, delivering $8.38 per share versus the $6.01 consensus, a $2.37 upside surprise that marked the largest beat in the trailing three-quarter sequence. Looking ahead, analyst estimates project EPS of $8.84 for the upcoming quarter with results expected on August 6, 2026. The trajectory of expanding earnings surprises reflects the accelerating revenue contribution from the company's GLP-1 franchise, per analyst estimates, with each successive quarter demonstrating widening outperformance relative to Wall Street expectations.
Wall Street consensus on Eli Lilly remains unanimously bullish, with all five most recent analyst actions reiterating positive ratings, according to Wall Street analyst reports. On August 7, 2026, Truist Securities maintained its Buy rating on LLY. One day prior, both Wells Fargo and Cantor Fitzgerald reiterated Overweight designations, reflecting sustained conviction following the company's earnings release. Citigroup reaffirmed its Buy rating on July 15, 2026, while Bernstein maintained an Outperform call on July 14, 2026, per SID consensus data. Notably, none of the five most recent analyst actions involved a rating change, with each firm maintaining its prior bullish stance, indicating stable and deeply held positive conviction across the sell-side community. The consistency of these reiterations suggests that Eli Lilly's fundamental trajectory, particularly its earnings outperformance pattern, continues to meet or exceed the frameworks underpinning these recommendations. No downgrades or neutral initiations appear among recent coverage actions for the stock.
The latest Smart Investors Daily articles mentioning LLY.
